GeoVax Labs Files Material Definitive Agreement 8-K
Ticker: GOVX · Form: 8-K · Filed: Sep 25, 2024 · CIK: 832489
Sentiment: neutral
Topics: material-agreement, filing
Related Tickers: GOVX
TL;DR
GeoVax Labs just signed a big deal, details to come.
AI Summary
On September 25, 2024, GeoVax Labs, Inc. filed an 8-K report detailing a material definitive agreement. The filing does not specify the other party involved in the agreement or the financial terms, but it indicates a significant event for the company.
Why It Matters
This filing signals a new significant business development for GeoVax Labs, Inc., potentially impacting its operations and future strategic direction.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which could be positive or negative depending on the undisclosed terms.
Key Players & Entities
- GeoVax Labs, Inc. (company) — Registrant
- September 25, 2024 (date) — Date of report
FAQ
What is the nature of the material definitive agreement filed by GeoVax Labs, Inc.?
The filing states that the report concerns an 'Entry into a Material Definitive Agreement' but does not provide specific details about the agreement itself within the provided text.
Who is the other party to the material definitive agreement?
The provided text of the 8-K filing does not disclose the name of the other party involved in the material definitive agreement.
What are the key financial terms or implications of this agreement?
The filing does not specify any financial terms or dollar amounts associated with the material definitive agreement.
When was this material definitive agreement entered into?
The report is dated September 25, 2024, and the earliest event reported is also September 25, 2024, suggesting the agreement was entered into on or around this date.
Are there any exhibits attached to this 8-K filing that might provide more details?
The filing indicates 'Financial Statements and Exhibits' are included, but the specific content of these exhibits is not detailed in the provided text.
Filing Stats: 1,105 words · 4 min read · ~4 pages · Grade level 8.8 · Accepted 2024-09-25 17:21:09
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share GOVX The Nasdaq Capital M
- $50,000 — certain specified expenses of (a) up to $50,000 in connection with the execution and im
- $5,000 — on of the Sales Agreement and (b) up to $5,000 per calendar quarter thereafter pursuan
- $4,486,846 — or an aggregate offering price of up to $4,486,846. The foregoing summary of the Sales Ag
Filing Documents
- govx20240924_8k.htm (8-K) — 32KB
- ex_727126.htm (EX-5.1) — 13KB
- ex_727127.htm (EX-10.1) — 235KB
- l01.jpg (GRAPHIC) — 5KB
- l02.jpg (GRAPHIC) — 25KB
- logo.jpg (GRAPHIC) — 24KB
- 0001437749-24-029998.txt ( ) — 562KB
- govx-20240925.xsd (EX-101.SCH) — 4KB
- govx-20240925_def.xml (EX-101.DEF) — 14KB
- govx-20240925_lab.xml (EX-101.LAB) — 18KB
- govx-20240925_pre.xml (EX-101.PRE) — 14KB
- govx20240924_8k_htm.xml (XML) — 5KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On September 25, 2024, GeoVax Labs, Inc. (the "Company") entered into a Sales Agreement (the "Sales Agreement") with A.G.P./Alliance Global Partners ("A.G.P."), as agent, pursuant to which we may offer and sell, from time to time through or to A.G.P., as sales agent or principal, shares of our common stock, $0.001 par value per share. We are not obligated to make any sales of our common stock under the Sales Agreement and no assurance can be given that we will sell any shares under the Sales Agreement, or, if we do, as to the price or number of shares that we will sell, or the dates on which any such sales will take place. The Sales Agreement will terminate upon the earlier of (i) the sale of all shares under the Sales Agreement, or (ii) as provided therein. Sales of shares of
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 5.1 Opinion of Womble Bond Dickinson (US) LLP. 10.1 Sales Agreement, by and between the Company and A.G.P./Alliance Global Partners, dated September 25, 2024. 23.1 Consent of Womble Bond Dickinson (US) LLP (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: September 25, 2024 GEOVAX LABS, INC. By: /s/ Mark W. Reynolds Mark W. Reynolds Chief Financial Officer